• Latest
  • Trending
  • All
  • News
  • Business
  • Politics
  • Science
  • World
  • Lifestyle
  • Tech
Researchers: Breast Cancer Drug Could Help More Patients | Health News

Researchers: Breast Cancer Drug Could Help More Patients | Health News

June 5, 2022
Senate Education Discusses Financial Literacy, Free Period Products

Senate Education Discusses Financial Literacy, Free Period Products

February 2, 2023
Post-Global War on Terror, different missions for the National Guard

Post-Global War on Terror, different missions for the National Guard

February 2, 2023
USWNT World Cup roster prediction 4.0: How SheBelieves Cup could impact selections

USWNT World Cup roster prediction 4.0: How SheBelieves Cup could impact selections

February 2, 2023
ChildCare Education Institute launches CUR137: Completing

ChildCare Education Institute launches CUR137: Completing

February 2, 2023
Gaps in Mental Health Care for Asian and Pacific Islander People and Other People of Color

Gaps in Mental Health Care for Asian and Pacific Islander People and Other People of Color

February 2, 2023
Jean-Pierre calls Texas border czar a ‘political stunt,’ claims Biden’s actions ‘made a difference’

Jean-Pierre calls Texas border czar a ‘political stunt,’ claims Biden’s actions ‘made a difference’

February 2, 2023
House Ousts Ilhan Omar From Foreign Affairs Panel

House Ousts Ilhan Omar From Foreign Affairs Panel

February 2, 2023
National Wear Red Day declared for Friday, aims to bring awareness and fight heart disease

National Wear Red Day declared for Friday, aims to bring awareness and fight heart disease

February 2, 2023
New Report Looks at Arkansas Policies To Promote Infant, Toddler Health

New Report Looks at Arkansas Policies To Promote Infant, Toddler Health

February 2, 2023
Kyle Rittenhouse: Victim’s father’s wrongful-death lawsuit can proceed

Kyle Rittenhouse: Victim’s father’s wrongful-death lawsuit can proceed

February 2, 2023
Trump Won’t Commit to Backing the G.O.P. Nominee in 2024

Trump Won’t Commit to Backing the G.O.P. Nominee in 2024

February 2, 2023
Riviera Beach classroom gets ‘STEM’ makeover thanks to FPL grant

Riviera Beach classroom gets ‘STEM’ makeover thanks to FPL grant

February 2, 2023
Wednesday, February 8, 2023
News Today
  • Home
  • World
  • Politics
  • Health
  • Education
  • National
  • News
No Result
View All Result
News Today
No Result
View All Result
Home Health

Researchers: Breast Cancer Drug Could Help More Patients | Health News

by newstoday
June 5, 2022
in Health
0
Researchers: Breast Cancer Drug Could Help More Patients | Health News
493
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter


By CARLA K. JOHNSON, AP Medical Writer

For the first time, a drug targeting a protein that drives breast cancer growth has been shown to work against tumors with very low levels of the protein.

It’s not a cure. But this latest gain for targeted cancer therapy could open new treatment possibilities to thousands of patients with advanced breast cancer.

Until now, breast cancers have been categorized as either HER2-positive — the cancer cells have more of the protein than normal — or HER2-negative. Doctors reporting the advance Sunday said it will make “HER2-low” a new category for guiding breast cancer treatment.

About half of patients with late-stage breast cancer formerly categorized as HER2-negative may actually be HER2-low and eligible for the drug.

Political Cartoons

The drug is Enhertu, an antibody-chemotherapy combo given by IV. It finds and blocks the HER2 protein on cancer cells, while also unloading a powerful cancer-killing chemical inside those cells. It belongs to a relatively new class of drugs called antibody-drug conjugates.

The drug was already approved for HER2-positive breast cancer, and in April the Food and Drug Administration granted it breakthrough status for this new group of patients.

In the new study, the drug lengthened the time patients lived without their cancer progressing and improved survival compared with patients given standard chemotherapy.

The study compared Enhertu to standard chemo in about 500 patients with HER2-low breast cancer that had spread or could not be treated with surgery. The drug stopped the progress of cancer for about 10 months compared with about 5 1/2 months in the group getting regular care. The drug improved survival by about six months (from 17.5 months to 23.9 months).

“It’s a practice-changing study,” said Dr. Sylvia Adams, who directs breast cancer care at NYU Langone Health and enrolled several patients in the study. “It addresses a major unmet need for patients who have metastatic breast cancer.”

Now, it will be important to define the HER2 gray area to make sure the right patients receive the treatment and then to monitor them closely, experts said.

The drug, which costs about $14,000 a month, can have severe complications. Three patients in the study died of a lung disease that’s a known hazard of the drug. Doctors need to make sure patients report breathing problems right away so the drug can be stopped and patients treated with steroids.

The findings were featured Sunday at the annual meeting of the American Society of Clinical Oncology in Chicago and published by the New England Journal of Medicine. Funding for the study came from Tokyo-based Daiichi Sankyo and U.K.-based AstraZeneca, which jointly developed the drug.

Patients take the drug until they can no longer tolerate it.

“A lot of people, including a lot of patients, will not have heard of HER2-low breast cancer before,” said the study’s lead author, Dr. Shanu Modi of Memorial Sloan Kettering Cancer Center in New York.

“We finally have a HER2-targeted drug that for the first time can target that low level of HER2 expression,” Modi said. “This drug actually helps to define HER2-low breast cancer. It makes it, for the first time, a targetable population.”

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Copyright 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.



Source link

Share197Tweet123Share49
newstoday

newstoday

  • Trending
  • Comments
  • Latest
Stay away from S.F. national parks, police union says. Here’s what’s behind the warning

Stay away from S.F. national parks, police union says. Here’s what’s behind the warning

May 25, 2022
Gallaudet University Track Star Becomes School’s First National Champ – NBC4 Washington

Cornyn likens overrule of Roe v. Wade to Brown v. Board of Education in tweet

June 26, 2022
John Cornyn tweet about Brown v. Board of Education goes viral

John Cornyn tweet about Brown v. Board of Education goes viral

June 25, 2022
African diplomats protest alleged begins racism and inhumane clinical treat

Coronavirus: France deaths at city 14,400 ahead Macron lockdown

0
Police investigating fatal shooting in southeast

Police investigating fatal shooting in southeast

0
African diplomats protest alleged begins racism and inhumane clinical treat

Prince Harry drops royal surname after moving

0
Senate Education Discusses Financial Literacy, Free Period Products

Senate Education Discusses Financial Literacy, Free Period Products

February 2, 2023
Post-Global War on Terror, different missions for the National Guard

Post-Global War on Terror, different missions for the National Guard

February 2, 2023
USWNT World Cup roster prediction 4.0: How SheBelieves Cup could impact selections

USWNT World Cup roster prediction 4.0: How SheBelieves Cup could impact selections

February 2, 2023
News Today

Copyright © 2022 NewsToday.

Navigate Site

  • Home
  • About us
  • Contact us
  • DMCA
  • Privacy Policy

Follow Us

No Result
View All Result
  • Home
  • News
    • Politics
    • Business
    • World
    • Science
  • Entertainment
    • Gaming
    • Music
    • Movie
    • Sports
  • Tech
    • Apps
    • Gear
    • Mobile
    • Startup
  • Lifestyle
    • Food
    • Fashion
    • Health
    • Travel

Copyright © 2022 NewsToday.